MASSACHUSETTS GENERAL HOSPITAL
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1811-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
2.5k
Trial Phases
6 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (2066 trials with phase data)β’ Click on a phase to view related trials
Mindfulness-based Cognitive Therapy for the Chronic Pain-early Cognitive Decline Co-morbidity Among Older Black Individuals in the Community; The Feeling of Being Open Pilot
- Conditions
- Chronic PainEarly Cognitive Decline
- First Posted Date
- 2025-10-07
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT07210398
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
Time Restricted Eating (TRE) in Bipolar Disorder
- Conditions
- Bipolar Disorder (BD)Bipolar Disorder DepressionOverweight (BMI > 30)
- First Posted Date
- 2025-10-07
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT07211217
EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Activin ligand-trap biological therapyDrug: Placebo, Normal Saline
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT07202000
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
- Conditions
- HIVSubstance Use Disorder (SUD)Injection Drug Use
- Interventions
- Drug: APRETUDE (cabotegravir)
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT07199335
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈFenway Health, Boston, Massachusetts, United States
HIV Self-testing for Partners of HIV-uninfected Postpartum Women
- Conditions
- HIV Self-testingHIV PreventionMale Partners of HIV-negative Postpartum WomenPrEP UptakeFeasibilityAcceptability
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT07194902
- Locations
- πΏπ¦
Wits MatCH Research Unit, Durban, KwaZulu-Natal, South Africa
- Prev
- 1
- 2
- 3
- 4
- 5
- 492
- Next
News
Wearable Heart Rate Variability Patch Reduces Substance Use by 64% in Recovery Patients
Mass General Brigham researchers demonstrated that a wearable heart rate variability biofeedback device significantly reduced substance cravings and use in early recovery patients.
SELLAS Life Sciences Announces R&D Day to Showcase Phase 3 AML Trial Results and CDK9 Inhibitor Program
SELLAS Life Sciences will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders discussing acute myeloid leukemia treatment advances and unmet medical needs.
FDA Clears Clinical Trial for Pig Kidney Transplants as Second Patient Achieves Dialysis-Free Life
Bill Stewart, a 54-year-old New Hampshire man, successfully received a genetically engineered pig kidney transplant on June 14 and no longer requires dialysis after being discharged from Massachusetts General Hospital.
Treeline Biosciences Initiates Three Phase 1 Trials Targeting BCL6, KRAS, and EZH2 with $1.1B in Total Funding
Treeline Biosciences has launched Phase 1 clinical trials for three oncology programs: TLN-121 (BCL6 degrader), TLN-372 (pan-KRAS inhibitor), and TLN-254 (EZH2 inhibitor) targeting lymphomas and solid tumors.
Personalized ALS Drug Shows Breakthrough Results, Slowing Disease Progression by More Than Half
A custom-built antisense oligonucleotide drug targeting the CHCHD10 gene mutation has slowed ALS progression by more than half in Dr. Rakesh Parekh, marking the first treatment for this specific genetic variant.
Thryv Therapeutics Unveils Breakthrough SGK1 Inhibitor Data for Heart Failure and Long QT Syndrome at ESC Congress 2025
Thryv Therapeutics will present compelling preclinical results for THRV-1268, a best-in-class SGK1 inhibitor, at the European Society of Cardiology Congress 2025 in Madrid.
UMass Chan Gene Therapy Shows Biochemical Correction in GM2 Gangliosidosis Phase I/II Trial
A Phase I/II clinical trial at UMass Chan Medical School demonstrated biochemical correction of GM2 gangliosidosis using dual vector gene therapy with minimal adverse reactions.
High-Volume Cancer Centers with Greater Neoadjuvant Chemotherapy Use Show Reduced Mortality in Advanced Ovarian Cancer
Institutions with high utilization of neoadjuvant chemotherapy for advanced ovarian cancer demonstrated significantly lower 90-day postoperative mortality rates across all hospital volume categories.
Progressive Supranuclear Palsy Market Poised for Growth as Emerging Therapies Advance Through Clinical Trials
The progressive supranuclear palsy (PSP) market is experiencing significant growth driven by emerging therapies including AZP2006 and AMX0035, which are advancing through clinical trials with promising results.
Mass General Brigham Launches Clinical Trials for Haystack MRD ctDNA Test in Head and Neck and Skin Cancers
Mass General Brigham has initiated two prospective clinical trials to evaluate Haystack MRD, a highly sensitive circulating tumor DNA test, for guiding postoperative treatment decisions in cutaneous squamous cell carcinoma and HPV-independent head and neck squamous cell carcinoma.